PaxMedica Inc. Common Stock
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.2612
- Today's High:
- $0.301
- Open Price:
- $0.301
- 52W Low:
- $0.2612
- 52W High:
- $4.39
- Prev. Close:
- $0.282
- Volume:
- 311083
Company Statistics
- Market Cap.:
- $7.73 million
- Book Value:
- 0.147
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -330.38%
- Return on Equity TTM:
- 0%
Company Profile
PaxMedica Inc. Common Stock had its IPO on 2022-08-26 under the ticker symbol PXMD.
The company operates in the Healthcare sector and Biotechnology industry. PaxMedica Inc. Common Stock has a staff strength of 3 employees.
Stock update
Shares of PaxMedica Inc. Common Stock opened at $0.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.26 - $0.3, and closed at $0.29.
This is a +1.1% increase from the previous day's closing price.
A total volume of 311,083 shares were traded at the close of the day’s session.
In the last one week, shares of PaxMedica Inc. Common Stock have slipped by -39.34%.
PaxMedica Inc. Common Stock's Key Ratios
PaxMedica Inc. Common Stock has a market cap of $7.73 million, indicating a price to book ratio of 10.4824 and a price to sales ratio of 0.
In the last 12-months PaxMedica Inc. Common Stock’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures PaxMedica Inc. Common Stock's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PaxMedica Inc. Common Stock’s operating margin was 0% while its return on assets stood at -330.38% with a return of equity of 0%.
In Q2, PaxMedica Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
PaxMedica Inc. Common Stock’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.21 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PaxMedica Inc. Common Stock’s profitability.
PaxMedica Inc. Common Stock stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -5.8652. Its price to sales ratio in the trailing 12-months stood at 0.
PaxMedica Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.14 million
- Total Liabilities
- $2.43 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
PaxMedica Inc. Common Stock ended 2024 with $5.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.14 million while shareholder equity stood at $2.27 million.
PaxMedica Inc. Common Stock ended 2024 with $0 in deferred long-term liabilities, $2.43 million in other current liabilities, 1537.00 in common stock, $-41060050.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.07 million and cash and short-term investments were $3.07 million. The company’s total short-term debt was $1,611,336 while long-term debt stood at $53711.00.
PaxMedica Inc. Common Stock’s total current assets stands at $5.14 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $500000.00 compared to accounts payable of $658711.00 and inventory worth $0.
In 2024, PaxMedica Inc. Common Stock's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, PaxMedica Inc. Common Stock paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.29
- 52-Week High
- $4.39
- 52-Week Low
- $0.2612
- Analyst Target Price
- $
PaxMedica Inc. Common Stock stock is currently trading at $0.29 per share. It touched a 52-week high of $4.39 and a 52-week low of $4.39. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.64 and 200-day moving average was $1.61 The short ratio stood at 0.25 indicating a short percent outstanding of 0%.
Around 7301.3% of the company’s stock are held by insiders while 110.2% are held by institutions.
Frequently Asked Questions About PaxMedica Inc. Common Stock
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company’s lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company has a research collaboration with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.